World Health Organization guidance on the treatment of isoniazid-resistant tuberculosis
L. Gonzalez Angulo (Geneva, Switzerland), D. Falzon (Geneva, Switzerland), E. Jaramillo (Geneva, Switzerland), K. Weyer (Geneva, Switzerland)
Source: International Congress 2018 – New developments in tuberculosis
Session: New developments in tuberculosis
Session type: Oral Presentation
Number: 1957
Disease area: Respiratory infections
Abstract Background: isoniazid is a critical component of first-line tuberculosis (TB) treatment regimens. Even in the absence of resistance to rifampicin – another key anti-TB medicine - isoniazid-resistance (Hr-TB) lowers the effectiveness of these regimens. Evidence-based treatment recommendations for Hr-TB (present in ~8% of TB cases worldwide) are thus important.
Methods: in 2017, the World Health Organization (WHO) convened a multidisciplinary Guideline Development Group to advise it on Hr-TB treatment policy. The guidelines were prepared using the GRADE approach (www.gradeworkinggroup.org/). Individual patient data from ~5,500 Hr-TB cases in 33 observational studies worldwide were analysed. Recommendations were developed by the Guideline Development Group based on this evidence and on consideration of the balance of benefits and harms of different therapeutic options for the patients and caregivers.
Findings: upon the expert advice, WHO recommends that Hr-TB patients be treated with a 6-month regimen composed of rifampicin, ethambutol, pyrazinamide and levofloxacin (6REZLfx). Levofloxacin is only added to the regimen if rifampicin resistance has been reliably excluded. If the fluoroquinolone is contraindicated, treatment with a 6-month course of REZ alone is recommended. Streptomycin or other injectable agents are not usually recommended. All recommendations are conditional and based on a very low certainty in the estimates of effect.
Interpretation: the production of these guidelines has highlighted a shortage of high-quality evidence about the treatment of Hr-TB. Implementation research and trials of regimen effectiveness and safety (e.g. to limit duration of pyrazinamide use) would be desirable.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Gonzalez Angulo (Geneva, Switzerland), D. Falzon (Geneva, Switzerland), E. Jaramillo (Geneva, Switzerland), K. Weyer (Geneva, Switzerland). World Health Organization guidance on the treatment of isoniazid-resistant tuberculosis. 1957
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update Source: Eur Respir J , 49 (3) 1602308; DOI: 10.1183/13993003.02308-2016 Year: 2017
European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations Source: Eur Respir J, 52 (5) 1801617; 10.1183/13993003.01617-2018 Year: 2018
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Source: Eur Respir J, 57 (6) 2003300; 10.1183/13993003.03300-2020 Year: 2021
The World Health Organization standards for tuberculosis care and management Source: Eur Respir J, 51 (3) 1800098; 10.1183/13993003.00098-2018 Year: 2018
New treatment outcome definitions for drug-susceptible and drug-resistant tuberculosis: update from World Health Organization Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021
The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines Source: Eur Respir J, 54 (4) 1901272; 10.1183/13993003.01272-2019 Year: 2019
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization Source: Eur Respir J, 57 (4) 2100361; 10.1183/13993003.00361-2021 Year: 2021
World Health Organization treatment outcome definitions for tuberculosis: 2021 update Source: Eur Respir J, 58 (2) 2100804; 10.1183/13993003.00804-2021 Year: 2021
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country Source: Eur Respir J 2017; 49(1): 1601967; DOI: 10.1183/13993003.01967-2016 Year: 2017
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment Source: Eur Respir J 2015; 46: 1461-1470 Year: 2015
New definitions of extensively drug resistant tuberculosis: update from the World Health Organization Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe Source: Eur Respir J, 53 (6) 1900391; 10.1183/13993003.00391-2019 Year: 2019
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics Source: Eur Respir J 2016; 47:1867-1869 Year: 2016
The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis Source: Eur Respir J, 51 (3) 1701643; 10.1183/13993003.01643-2017 Year: 2018
World Health Organization Collaborating Centre for Research and Training in Management of MDR-TB – curricula and methods Source: Eur Respir J 2005; 26: Suppl. 49, 191s Year: 2005
The World Health Organization actions on digital health for tuberculosis: perspectives for respiratory medicine Source: Virtual Congress 2021 – Digital health in respiratory medicine: opportunities for everyone Year: 2021
The new World Health Organisation classification of lung cancer Source: International Congress 2016 – PG7 New guidelines for the classification and staging of lung cancer Year: 2016
The new World Health Organization classification of lung tumours Source: Eur Respir J 2001; 18: 1059-1068 Year: 2001